首页> 外文期刊>Plant Biotechnology Journal >Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR
【24h】

Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR

机译:植物衍生候选人免疫缺陷病毒1型粘膜疫苗CTB-MPR的生化和免疫表征

获取原文
获取原文并翻译 | 示例
       

摘要

Plants are potentially the most economical platforms for the large-scale production of recombinant proteins. Thus, plant-based expression of subunit human immunodeficiency virus type 1 (HIV-1) vaccines provides an opportunity for their global use against the acquired immunodeficiency syndrome pandemic. CTB-MPR[CTB, cholera toxin B subunit; MPR, membrane proximal (ectodomain) region of gp41] is an HIV-1 vaccine candidate that has been shown previously to induce antibodies that block a pathway of HIV-1 mucosal transmission. In this article, the molecular characterization of CTB-MPR expressed in transgenic Nicotiana benthamiana plants is reported. Virtually all of the CTB-MPR proteins expressed in the selected line were shown to have assembled into pentameric, GM1 ganglioside-binding complexes. Detailed biochemical analyses on the purified protein revealed that it was N-glycosylated, predominantly with high-mannose-type glycans (more than 75%), as predicted from a consensus asparagine-X-serine/threonine (Asn-X-Ser/Thr) N-glycosylation sequon on the CTB domain and an endoplasmic reticulum retention signal attached at the C-terminus of the fusion protein. Despite this modification, the plant-expressed protein retained the nanomolar affinity to GM1 ganglioside and the critical antigenicity of the MPR moiety. Furthermore, the protein induced mucosal and serum anti-MPR antibodies in mice after mucosal prime-systemic boost immunization. Our data indicate that plant-based expression can be a viable alternative for the production of this subunit HIV-1 vaccine candidate.
机译:植物可能是重组蛋白大规模生产的最经济性的平台。因此,基于植物的亚基人免疫缺陷病毒型(HIV-1)疫苗的表达为其全球使用免于获得的免疫缺陷综合症大流行提供了机会。 CTB-MPR [CTB,霍乱毒素B亚基; MPR,GP41的膜近端(Ectodomain)区域是HIV-1疫苗候选者,其先前已被诱导诱导阻断HIV-1粘膜透射途径的抗体。在本文中,报道了在转基因尼古特植物植物中表达的CTB-MPR的分子表征。实际上,所选生产线中表达的所有CTB-MPR蛋白被显示为组合成五聚体,GM1神经节苷脂结合络合物。纯化蛋白质的详细生化分析显示,它是N-糖基化,主要具有高甘露糖型聚糖(超过75%),从共有芦笋-X-丝氨酸/苏氨酸预测(ASN-X-SER / THR )在CTB结构域上的N-糖基化调味品和附着在融合蛋白的C-末端的内质网静脉保留信号。尽管这种修饰,但植物表达的蛋白质保留了对Gm1神经节苷脂的纳米摩尔亲和力和MPR部分的临界抗原性。此外,在粘膜原始 - 全身升压免疫后,蛋白质诱导的粘膜和血清抗MPR抗体。我们的数据表明,基于植物的表达可以是生产该亚基HIV-1疫苗候选者的可行替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号